hydron;N-[4-[1-[2-(6-methylpyridin-2-yl)ethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide;dichloride

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: hydron;N-[4-[1-[2-(6-methylpyridin-2-yl)ethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide;dichloride
• 化学式: C21H29Cl2N3O3S
• 分子量: 474.4
• InChiKey: ZQBNWMFBOSOOLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.74
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  87.8
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N-[4-(哌啶-4-羰基)-苯基]甲烷磺酰胺盐酸盐 、 2-甲基-6-乙烯基吡啶 、 sodium acetate 、 甲醇 在 乙醇 作用下， 以 mixture 、 水 为溶剂， 反应 2.0h， 以to obtain 0.285 g (yield: 81%) of the intended compound的产率得到hydron;N-[4-[1-[2-(6-methylpyridin-2-yl)ethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide;dichloride
  参考文献：
  名称：

  Piperidine derivative and pharmaceutical composition containing the same

  摘要：

  一种新的哌啶化合物在治疗心律失常方面具有药理学上的有效性，其化学式为：##STR1## 其中，R.sup.1是较低的烷基或甲苯基；R.sup.2是氢、较低的烷基、较低的烯基、环烷基或环烷基烷基；X是--CO--、--CH.sub.2--或--CHOH--；g和h的总和等于整数3或4，其中g和h分别为1、2或3；A是取代或未取代的烷基、烯基、--(CH.sub.2).sub.k--S--，其中k为2至5的整数，或--(CH.sub.2).sub.pCO--，其中p为1至4的整数；B是至少含有一个氮原子的杂环环。

  公开号：

  US05118689A1

文献信息

• SUBSTITUTED N-(3-PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS
  申请人：UNIVERSITY OF UTAH RESEARCH FOUNDATION

  公开号：US20150252048A1

  公开（公告）日：2015-09-10

  In one aspect, the invention relates to substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of the BTK kinase; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the BTK kinase. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在某个方面，本发明涉及替代N-(3-(嘧啶-4-基)苯基)丙烯酰胺类似物、其衍生物和相关化合物，它们可用作BTK激酶抑制剂；制备这些化合物的合成方法；含有这些化合物的药物组合物；以及使用这些化合物和组合物治疗与BTK激酶功能障碍相关的疾病的方法。本摘要旨在作为搜索特定领域的工具，不限制本发明。
• Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
  申请人：SignPath Pharma Inc.

  公开号：US10349884B2

  公开（公告）日：2019-07-16

  Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of IKr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.

  本发明提供了用于预防人或动物的一种或多种心脏通道病或因心脏形态不规则或改变或两者兼而有之而导致的病症的组合物和方法，其中包括：一种或多种药理活性制剂，通过抑制醚-a-go-go 相关基因（hERG）的活性而导致 IKr 通道抑制或 QT 延长中的至少一种；以及一种或多种脂质体，其中脂质体为空脂质体，并在施用药理活性制剂之前、同时或之后施用。
• Piperidine derivative, pharmaceutical composition containing the same and use
  申请人：Eisai Co., Ltd.

  公开号：EP0235752B1

  公开（公告）日：1993-11-18
• SUBSTITUTED N-(3-(PYRIMIDIN-4-YL)PHENYL)ACRYLAMIDE ANALOGS AS TYROSINE RECEPTOR KINASE BTK INHIBITORS
  申请人：University Of Utah Research Foundation

  公开号：EP2903972A2

  公开（公告）日：2015-08-12
• LIPOSOMAL MITIGATION OF DRUG-INDUCED INHIBITION OF THE CARDIAC IKR CHANNEL
  申请人：SignPath Pharma Inc.

  公开号：US20150164878A1

  公开（公告）日：2015-06-18

  Compositions and methods are provided for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject comprising: one or more pharmacologically active agents that causes at least one of I Kr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene (hERG); and one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent.